April 12, 2018 / 7:38 AM / 8 months ago

BRIEF-Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients

April 12 (Reuters) - Assembly Biosciences Inc:

* ASSEMBLY BIOSCIENCES PRESENTS POSITIVE INTERIM DATA FROM PHASE 1A AND 1B STUDIES OF ABI-H0731 IN HBV PATIENTS IN A LATE-BREAKER SESSION AT THE EASL CONFERENCE

* SAYS GENERALLY SAFE AND WELL TOLERATED; PLANNING UNDERWAY FOR PHASE 2A STUDIES BEGINNING SUMMER 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below